Fierce competition in the hepatitis C market has caused Gilead Sciences’ (NASDAQ:GILD) sales and share price to slide, but the dividend-paying company remains profitable and there are catalysts on the horizon that could reignite interest. Is now a good time to add this biotech behemoth to portfolios?
By the numbers
Gilead Sciences has been selling widely used HIV drugs for over a decade, but its recent woes stem from declining demand for its hepatitis C drugs. The company was the first drugmaker to develop oral medicines that provide functional cures for the liver disease. However, other drugmakers have rolled out their own treatments, sparking a price war that’s taken a toll on Gilead Sciences’ financial results.
IMAGE SOURCE: GETTY IMAGES.
Top Biotech Stocks For 2019: Rowan Companies Inc.(RDC)
- [By Shane Hupp]
Rowan Companies (NYSE:RDC) was downgraded by analysts at HSBC Holdings plc from a buy rating to a hold rating.
Roper Technologies (NYSE:ROP) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating.
- [By Matthew DiLallo]
While September was a good month for Ensco, the company made an even bigger splash in October by agreeing to buy fellow offshore driller Rowan (NYSE:RDC) in an all-stock deal. Ensco believes that the combination with Rowan will generate $150 million in annual cost savings while boosting its cash flow per share starting in 2020. It’s the company’s second major deal since the oil market downturn began; it bought Atwood Oceanics last year for $6.9 billion.
- [By Lisa Levin]
Check out these big penny stock gainers and losers
MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss.
Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings.
Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance.
Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results.
Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday.
BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years.
Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint.
Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results.
Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates.
Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share.
Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m
Top Biotech Stocks For 2019: Intersil Corporation(ISIL)
- [By Logan Wallace]
Media stories about Intersil (NASDAQ:ISIL) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intersil earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the semiconductor company an impact score of 46.0713234548749 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Top Biotech Stocks For 2019: Tandy Leather Factory, Inc.(TLF)
- [By Max Byerly]
Press coverage about Tandy Leather Factory (NASDAQ:TLF) has trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tandy Leather Factory earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave press coverage about the textile maker an impact score of 48.0642054684382 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
- [By Shane Hupp]
Tandy Leather Factory (NASDAQ: TLF) and Vera Bradley (NASDAQ:VRA) are both small-cap retail/wholesale companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.